ArticleNeuro-oncology advances
Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas.Scientific reports · 2022Pooled it
- Exogenous Hormones and Their Clinical Implications for the Development and Growth of Meningioma Tumours.Journal of clinical medicine · 2026Review
- Risk of intracranial meningioma requiring surgical intervention among recent hormonal contraceptives users.Journal of neuro-oncology · 2026Article
- The hormonal nexus in PIK3CA-mutated meningiomas: implications for targeted therapy and clinical trial design.Journal of neuro-oncology · 2025Review
- Advancements in the research of the structure, function, and disease-related roles of ARMC5.Frontiers of medicine · 2025Review
- Meningiomas in Rubinstein-Taybi syndrome: A case report and comprehensive review.Journal of neuropathology and experimental neurology · 2025Review
- Meningioma: Molecular Updates from the 2021 World Health Organization Classification of CNS Tumors and Imaging Correlates.AJNR. American journal of neuroradiology · 2025Review
- High prevalence of adrenal cortical adenomas in patients with cerebral meningiomas.Journal of endocrinological investigation · 2023Article
- Hormone therapies in meningioma-where are we?Journal of neuro-oncology · 2023Review
- Progestin-related WHO grade II meningiomas behavior-a single-institution comparative case series.Neurosurgical review · 2022Article
- Cyproterone acetate and meningioma: a nationwide-wide population based study.Journal of neuro-oncology · 2021Observational
- Multiple meningiomas: does quantity matter? a population-based survival analysis with underlined age and sex differences.Journal of neuro-oncology · 2020Article
- Highlights of the inaugural ten - the launch of Neuro-Oncology Advances.Neuro-oncology advancesArticle
- Prediction of meningioma shrinkage after cyproterone acetate cessation.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeningiomas are the most common primary intracranial tumors in adults. The relationship between meningiomas and exogenous sex hormones such as cyproterone acetate (CPA) is well documented, yet the underlying mechanisms remain unknown. Defining the histomolecular status of meningiomas developed on CPA would help us to better understand the oncogenesis of these tumors.
methodsWe identified 30 patients operated for a meningioma after long-term high-dose CPA therapy and with a history of CPA discontinuation before establishing the indication for surgical intervention. We used array-comparative genomic hybridization (to characterize copy number changes in those 30 meningiomas and subsequently performed next-generation sequencing with the National Institute of Cancer (INCa) solid tumor panel, which is a targeted panel of clinically actionable genes. We also examined grade, type, and clinical features.
resultsWe identified
conclusionOur study shows that low-grade meningothelial meningiomas of the skull base are predominant in CPA meningiomas. We identified PIK3CA/AKT1 pathway as a hypothetical actor in onco-pharmacological interaction between meningiomas and CPA. This signaling pathway could be an interesting target for precision medicine trials in meningioma patients who have been subjected to CPA. Our results could invite the scientific community to review the current classification of meningiomas and to evolve toward more specific histomolecular classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.